Profile Technologies (PRTK) Misses Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Paratek Pharmaceuticals (PRTK) Bullish Stance Reiterated at Cantor Fitzgerald as Pivotal Trials Brings NDA One Step Closer
August 5, 2015 11:33 AM EDTCantor Fitzgerald analyst Daniel Brims reiterated a Buy rating and $35 price target on Paratek Pharmaceuticals (NASDAQ: PRTK) as the company begins pivotal trials, bringing the NDA one step close.
Brims commented, "PRTK continues to advance its US clinical program, and we believe its oral... More
